Identification of CSRP1 as novel biomarker for hormone-sensitive prostate cancer by the combination of clinical and functional research
Abstract Prostate cancer (PCa) ranks as the second most common malignancy and the fifth leading cause of cancer-related deaths among men. A critical challenge lies in accurately identifying those patients at high risk for transitioning rapidly from hormone-sensitive PCa (HSPC) to lethal castration-r...
Saved in:
| Main Authors: | Chenxi Pan, Wei Wang, Yi He, Bo Yang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-02-01
|
| Series: | Cancer Cell International |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12935-025-03708-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Construction and validation of a nomogram for identifying the patients at risk for rapid progression of advanced hormone-sensitive prostate cancer
by: Xiaolong Xu, et al.
Published: (2025-04-01) -
Ultralow Prostate-specific Antigen Nadir After Apalutamide: Outcomes in Synchronous Versus Metachronous Metastatic Hormone-sensitive Prostate Cancer
by: Mike Wenzel, et al.
Published: (2025-07-01) -
Clinical efficacy of cytoreductive radical prostatectomy in the treatment of oligometastatic hormone-sensitive prostate cancer
by: Feng Qi, et al.
Published: (2025-01-01) -
CSRP2 promotes the glioblastoma mesenchymal phenotype via p130Cas-mediated NF-κB and MAPK pathways
by: Jiawei He, et al.
Published: (2025-08-01) -
Final analysis of ArtemisR, a European real-world retrospective study of apalutamide for the treatment of patients with metastatic hormone-sensitive prostate cancer
by: Martin Boegemann, et al.
Published: (2025-07-01)